CSIMarket Company Name, Ticker, Suppliers, else..
 
Fate Therapeutics Inc   (NASDAQ: FATE)
Other Ticker:  
 
 

Fate Therapeutics Inc Growth Comparisons

Select each growth Category to receive further Information



FATE Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) 58.13 % 13.29 % 7.3 % 3.85 %
Q / Q Revenue Growth (Q3 MRQ) -54.61 % 9.65 % 2.76 % 0.31 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) -87.34 % 5.2 % 5.66 % %
Seq. Revenue Growth (for 12 months ending Q3 TTM) 9.17 % 3.16 % 1.78 % 1.08 %
Revenue 5 Year Average Growth 68.05 % 7.75 % 8.02 % 7.61 %


FATE's Growth Comparisons in III. Quarter 2024




Fate Therapeutics Inc showed respectable 58.13% year on year rise of Revenue in the third quarter 2024, comparing favorably to the 13.29% rise in the Biotechnology & Pharmaceuticals industry, and 7.3% growth in the Healthcare sector. Above the average sales gains in the Healthcare and in the Biotechnology & Pharmaceuticals industry, helped to elevate overall market growth to 3.85%.

Top-line fell by -54.61% from the second quarter results. Comparing the annual growth, sales of 68.05% on average in last five years, to the S & P 500's, including only Businesses with the third quarter 2024 financial results, average yearly sales growth is 7.61%. Fate Therapeutics Inc grew faster than the market.

FATE Growth Rates by Company's Segments

Segment Name
Y / Y
Seq.
Total
58.13 %
-54.61 %


Growth Rates of FATE's Income in the third quarter 2024


FATE Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) - 269.01 % 79.88 % 4.22 %
Seq. Operating Income Change (Q3 MRQ) - -27.4 % 33.31 % -2.5 %
Y / Y Operating Income Growth (Q3 TTM) - -91.35 % -5.85 % 9.02 %
Seq. Operating Income Growth (Q3 TTM) - - 19.89 % 1.36 %
Operating Income 5 Year Avg. Change - - 6.12 % 9.13 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) - - 284.25 % -1.75 %
Seq. Income from Cont. Ops. Change (Q3 MRQ) - 347.23 % 118.94 % -8.86 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) - - 26.21 % 8.51 %
Seq. Income from Cont. Ops. Change (Q3 TTM) - - 56.32 % -0.08 %
Income from Cont. Ops. 5 Year Avg. Change - - -9.76 % 7.3 %

FATE Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) - - 7.9 % -6.44 %
Q / Q Net Income Growth (Q3 MRQ) - 347.11 % 132.5 % -6.89 %
Y / Y Net Income Change (Q3 TTM) - - -10.96 % 4.96 %
Seq. Net Income Change (Q3 TTM) - - 2.5 % -1.41 %
Net Income 5 Year Avg. Growth - - -3.41 % 7.44 %

FATE's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) - - 284.25 % -1.75 %
Seq. EPS from Cont. Ops. Change (Q3 MRQ) - 343.54 % 118.94 % -8.86 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) - - - -
Seq. EPS from Cont. Ops. Change (Q3 TTM) - - - -6.57 %
EPS from Cont. Ops. 5 Year Avg. Growth - - -9.76 % 7.3 %



FATE EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) - - 7.9 % -6.44 %
Q / Q EPS Net Growth (Q3 MRQ) - 343.43 % 132.5 % -6.89 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - 44.84 %
Seq. EPS Net Change (for 12 months ending Q3 TTM) - - - -6.16 %
EPS Net 5 Year Avg. Change - - -3.41 % 7.44 %



Fate Therapeutics Inc reported bottom-line of $ -0.40 in the third quarter, compare to $ -0.46 in the same quarter a year ago. Biotechnology & Pharmaceuticals industry grew by 13.29%, while Healthcare sector increased by 7.9%, and overall market declined by -6.44%.

Bottom-line fell by -54.61% from the second quarter results. Comparing the annual growth, income per share of 68.05% on average in last five years, to the S & P 500's, including only Businesses with the third quarter 2024 earnings, average yearly income per share growth is 7.44%. Fate Therapeutics Inc grew faster than the market.

FATE Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) - 164.56 % 37.8 % -41.98 %
Seq. Free Cash Flow Change (Q3 MRQ) - 144.63 % 107.48 % -35.8 %
Y / Y Free Cash Flow Change (Q3 TTM) - -0.53 % 4.23 % 3.46 %
Seq. Free Cash Flow Change (Q3 TTM) - 32.62 % 8.11 % -10.66 %
Free Cash Flow 5 Year Avg. Change - -28.29 % 7 % 11.94 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - - -79.63 % -
Seq. Net Cash Flow Change (Q3 MRQ) - - - -
Y / Y Net Cash Flow Change (Q3 TTM) - - - -
Seq. Net Cash Flow Change (Q3 TTM) - - - -
Net Cash Flow 5 Year Avg. Change - 4.42 % 11.22 % -33.53 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) -12.39 % 4.14 % 1.51 % 2.82 %
Seq. Capital Expenditures Change (Q3 MRQ) 870.59 % 5.86 % 5.72 % 3.24 %
Y / Y Capital Expenditures Change (Q3 TTM) -93.57 % 5.32 % 3.04 % 69.35 %
Seq. Capital Expenditures Change (Q3 TTM) -7.93 % 0.46 % 2.02 % -0.5 %
Capital Expenditures 5 Year Avg. Change - -1.88 % 9.35 % 8.99 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com